Pharma's Almanac: Nice Insight's Content Community

Optimized Residual dsRNA Detection for mRNA Therapeutics

A team of experts from Samsung Biologics discusses the company’s development of a superior ELISA-based method for dsRNA detection that ensures greater accuracy and reliability.

Ophthalmology

Sep 16, 2024

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Tracey Roberts, Jennifer Christiansen, Ph.D., and Debra Schaumberg, Sc.D., O.D., all with the PPD™ clinical research business of Thermo Fisher Scientific, discuss the growth and challenges of global, late-stage ophthalmology clinical trials and the key drivers of proactive planning for success.

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Biopharma

Sep 27, 2024

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Fab Biopharma’s Reiner Getz, Ph.D., and Gardiner Smith, J.D. discuss how the company aims to revolutionize the treatment of complex and often life-threatening autoimmune diseases like Sjögren’s disease and lupus with its groundbreaking soluble bispecific receptor therapies

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Cell Therapy

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

In this Q&A, OrganaBio’s Chief Executive Officer Justin Irizarry discusses the strategies and operational philosophies driving the company and how it plans to navigate future challenges and opportunities in the rapidly evolving cell therapy landscape.

Bioassays

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Tanvex CDMO’s Anke Hartung, Ph.D., discusses her team’s development of novel analytical tools to assess the enhancement of the antibody-dependent cellular cytoxicity response of an anticancer monoclonal antibody drug.

Commercialization

Sep 17, 2024

Development Strategies for Overcoming Commercialization Challenges

Coriolis Pharma’s Matthias Lucke, Ph.D., discusses how a seamless integration of services that accelerates drug development while mitigating risks associated with transitions between different development phases ensures a streamlined path to market.

Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Touchlight’s Elena Stoyanova, Ph.D., and Tom Adie, Ph.D., explain how the company’s new nonviral MegaBulb DNA (mbDNA) offers a high-purity, synthetic CRISPR ssDNA template that demonstrates remarkable efficiency and minimal toxicity.

News

FDA

U.S. Food and Drug Administration

FDA

FDA Approves IMULDOSA, Accord BioPharma's Biosimilar to STELARA, for the Treatment of Chronic Inflammatory Conditions

FDA

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia

CDMO

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

Appointment

Oct 11, 2024

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

Clinical Trials

Oct 11, 2024

Harbour BioMed Announces the Phase I Study Results in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

The Road to the Max: Australia

Top 5

dbDNA

Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA

Top 5

Female-Centric

Sep 10, 2024

Transforming Drug Development through a Female Perspective

RoundTable

View all roundtable

RoundTable Topics

Unmet medical needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Sergey Vlasenko, Ph.D.

Frank Romanski, Ph.D.

David Fischer, Ph.D.

Jeff Elton, Ph.D.

Paula Ragan, Ph.D.

The next innovations in rare disease treatments will likely leverage investments into novel biologic drug modalities, such as oligonucleotide therapeutics and gene editing treatments.

View all Answers

RoundTable

View all roundtable

Unmet medical needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Sergey Vlasenko, Ph.D.

Frank Romanski, Ph.D.

David Fischer, Ph.D.

Jeff Elton, Ph.D.

Paula Ragan, Ph.D.

The next innovations in rare disease treatments will likely leverage investments into novel biologic drug modalities, such as oligonucleotide therapeutics and gene editing treatments.

View all Answers

RoundTable Topics

Unmet medical needs

Personalized and Precision Medicine

Innovation

Predictions

Lessons from the Pandemic

Milestones

Therapeutic Areas

Challenges

U.S. Market

Outsourcing Dynamics

Social Media Marketing

Investment Trends

Virtual BD and Marketing

Dealing with a Crisis

Post-COVID-19 Supply Chain

Global Access

Year in Review

2021 Projections

Evolving Technologies

Digital Connections

Leadership

Regulatory

Sustainability

Now Trending

Biotech

Sep 23, 2024

Five Small Biotechs to Watch: October 2024

Bioassays

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

Expansion

Sep 09, 2024

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

Process Development

Sep 24, 2024

Economic Benefits of Digital Process Development

Revolutionizing Biologics (and Biology) through a Focus on Women

Women's Health

Jul 09, 2024

Revolutionizing Biologics (and Biology) through a Focus on Women

Commercialization

Sep 17, 2024

Development Strategies for Overcoming Commercialization Challenges

Transforming Precision Medicine through a High-Resolution Temporal Exposome Platform

Exposomics

Sep 05, 2024

Transforming Precision Medicine through a High-Resolution Temporal Exposome Platform

Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

DoE for Clone Selection and Process Development to Meet Biosimilar Critical Qualities Attributes and High Productivity

Biosimilars

Sep 12, 2024

DoE for Clone Selection and Process Development to Meet Biosimilar Critical Qualities Attributes and High Productivity

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Developability

Sep 04, 2024

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Cell Therapy

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Ophthalmology

Sep 16, 2024

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Biopharma

Sep 27, 2024

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Nanocarriers to Overcome the Blood–Brain Barrier (BBB)

Drug Delivery

Aug 30, 2024

Nanocarriers to Overcome the Blood–Brain Barrier (BBB)

Transforming Drug Development through a Female Perspective

Female-Centric

Sep 10, 2024

Transforming Drug Development through a Female Perspective

RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

Videos

View all videos

Data Connectivity

Jan 19, 2022

Discussing the Advancements in Oncology

Tim Roberts, Chief Commercial Officer of PCI Pharma Services, sat down with Pharma’s Almanac’s Scientific Editor in Chief David Alvaro to discuss the advancements in oncology, the impact the COVID-19 pandemic has had on the industry, and why PCI is well-positioned to be a successful company for years to come.

Data Connectivity

Jan 19, 2022

Discussing the Advancements in Oncology

Biologics CDMO

Jan 26, 2022

Growing as a Trusted, Dedicated Commercial Biologics CDMO

Failure to Launch

Aug 07, 2024

Disaster Strikes

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Immuno-Oncology

May 24, 2022

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Decentralized Clinical Trials

Nov 17, 2022

The Evolving Role of Remote Monitoring

Transforming Market Insights into Growth

Marketing

May 09, 2022

Transforming Market Insights into Growth

Meet the Crew

Aug 07, 2024

Assembling the Crew

Stem Cell Therapy

Dec 12, 2023

Designing A Recipe for Stem Cell Therapy Success

The Power of Aqueous Detergents in Critical Cleaning

Aqueous Cleaning

Dec 05, 2023

The Power of Aqueous Detergents in Critical Cleaning

Supply Chain

Dec 12, 2023

Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience

Preparing to Launch

Aug 07, 2024

Preparing the Yacht for the Race

Setting Sail

Aug 07, 2024

Sailing into the Trade Winds

In Focus

Comparability

Aug 26, 2024

Leveraging Risk Assessment for Demonstrating Product Comparability after Manufacturing Process Changes

Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA

Synthetic DNA

Jul 02, 2024

Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA

Expansion

Sep 09, 2024

Building on a Pioneering Biomanufacturing Legacy with Client Centricity

CDMO Model

Jul 29, 2024

Rethinking the Conventional CDMO Model

Developability

Aug 26, 2024

Assessing Developability and Designing Advanceable Formulations from the Start

Developability

Sep 04, 2024

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Latest

View all latest

Financing

Oct 15, 2024

Why Life Science Companies Surged amid a Global M&A Downturn

CDMO

Oct 07, 2024

Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO

AI

Oct 07, 2024

Plan Ahead: Mastering Your AI Budget for 2025 Success

RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

Bioassays

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Cell Therapy

Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future

Gene Editing

Academia CDMO Clinical CRO Drug Discovery Early R&D Excipients / Intermediates Financing Equipment Preclinical CRO Supply Chain Technology

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Biopharma

Sep 27, 2024

Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors

Areas of Interests

A comprehensive market analysis with 110 major company profiles and detailed CDMO pricing information.

Over 60 company profiles covering the leading mRNA and LNP contract manufacturing organizations. Unique pricing comparison for the end-to-end manufacturing process.

Optimize your manufacturing process using 50+ established CDMO overviews and a requisite pricing study for small, mid sized and large manufacturers.

Comprehensive analysis of mammalian cell culture CDMOs including price benchmarking, market trends and over 80 company profiles.

Over 80 company profiles and analysis of leading microbial fermentation CDMO; exclusive market analysis and price comparison.

Understand the emerging ADC market with profiles on 30 notable CDMOs and an analysis of the value chain of mAbs, linkers and payloads. Benchmark with robust manufacturing pricing.

Exclusive pricing from 20+ CDMOs and market insight for pDNA as a reagent for advanced therapies and as a primary therapeutic.

Robust analysis of gene therapy market, includes 50 company profiles of AAV, Lentiviral and non-viral gene therapy CDMOs.

Discover the cell therapy market with unique insights, analysis, and overviews of allogeneic and autologous cell therapy CDMOs.

Over 80 extensive CDMO profiles for an all-encompassing benchmarking report. Exclusive pricing comparison and updated global GMP regulatory landscape

Discover the cell therapy market with unique insights, analysis, and overviews of allogeneic and autologous cell therapy CDMOs.